Cargando…
Lacosamide may improve cognition in patients with focal epilepsy: EpiTrack to compare cognitive side effects of lacosamide and carbamazepine
Carbamazepine (CBZ) is a first generation anti-seizure drug, considered as first choice therapy in focal epilepsy but associated with cognitive side effects. Lacosamide (LCM) is a third-generation anti-seizure drug approved for treating focal epilepsy. This case series documented the comparable effi...
Autores principales: | Liguori, Claudio, Izzi, Francesca, Manfredi, Natalia, Mercuri, Nicola Biagio, Placidi, Fabio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6030027/ https://www.ncbi.nlm.nih.gov/pubmed/29977793 http://dx.doi.org/10.1016/j.ebcr.2018.02.004 |
Ejemplares similares
-
Lacosamide as add-on treatment of focal symptomatic epilepsy in a patient with alcoholic liver cirrhosis
por: Romigi, A., et al.
Publicado: (2014) -
Effects of lacosamide and carbamazepine on lipids in a randomized trial
por: Mintzer, Scott, et al.
Publicado: (2020) -
Efficacy and safety of lacosamide in the treatment of status epilepticus in a patient with comorbidities
por: Mascolo, Alfredo Paolo, et al.
Publicado: (2021) -
Unmasking of myoclonus by lacosamide in generalized epilepsy
por: Birnbaum, Daniel, et al.
Publicado: (2016) -
Long‐term safety and efficacy of lacosamide and controlled‐release carbamazepine monotherapy in patients with newly diagnosed epilepsy
por: Ben‐Menachem, Elinor, et al.
Publicado: (2019)